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The International Agency for Research on
Cancer (1980, 1987) identiﬁes inhalation of
inorganic arsenic as a cause of lung cancer in
humans. The evidence has come primarily
from epidemiologic studies of miners and
smelter workers who inhaled high levels of
inorganic arsenic in airborne dust. Although
increased risk of lung cancer from inhaled
arsenic appears related to direct effects on the
respiratory tract, there may be a systemic
effect as well, because ingestion of high
amounts of inorganic arsenic in drinking
water has been associated with lung cancer
mortality at levels comparable with occupa-
tional risks from inhaled arsenic (Bates et al.
1992; Lubin et al. 2000). Information on the
mathematical relationship between cumulative
inhaled arsenic exposure and respiratory can-
cer mortality is limited. Although a compara-
tive evaluation of several occupational cohorts,
mostly smelter workers, suggested a concave
relationship between respiratory cancer mor-
tality and cumulative arsenic exposure (Hertz-
Picciotto and Smith 1993), a subsequent
update of one large study revealed that its
apparent nonlinearity was an artifact of expo-
sure assessment and that relative risk (RR)
trends with cumulative arsenic exposure were
consistent with a linear relationship (Lubin
et al. 2000). Previous analyses have focused on
cumulative arsenic exposure and the shape of
the exposure–response relationship, without
considering the possible influence of arsenic
concentration.
In the present analysis, we applied a novel
methodology used previously in a study of
smoking-related lung cancer (Lubin and
Caporaso 2006) to model cumulative arsenic
exposure and arsenic concentration. In partic-
ular, we examined the consequences of expo-
sure “delivery,” that is, whether the RR of
respiratory cancer at a ﬁxed cumulative expo-
sure delivered at higher arsenic concentration
for shorter duration was greater than, equal to,
or less than the RR from an equal cumulative
exposure delivered at lower concentration for
longer duration. We refer to these patterns as
direct (increasing), constant (no variation), or
inverse (decreasing) “exposure rate” effects. 
Standard analyses of joint RRs by duration
of arsenic exposure and arsenic concentration
with nonexposed individuals as the referent
group are problematic for characterizing the
effects of arsenic concentration, because cumu-
lative exposure varies. For illustration, consider
duration of cigarette smoking, smoking inten-
sity (cigarettes smoked per day), and total
pack-years (years of smoking times cigarettes
per day divided by 20). In a standard log-linear
RR regression model that includes duration of
smoking and cigarettes per day, the intensity
parameter represents the ln(RR) per cigarette
per day at a ﬁxed duration. Interpretation of
the duration parameter is similar but at a ﬁxed
intensity. A comparison of RRs at two differ-
ent intensities reﬂects not only different inten-
sities, but also different total pack-years. For
example, at 30 years’ duration, RRs at 20 and
30 cigarettes per day reﬂect different intensities
and different total pack-years—namely, 30
and 45 pack-years, respectively. Thus, RR pat-
terns with duration and intensity cannot be
viewed as “independent” because of the intrin-
sic confounding of pack-years. In contrast, in a
model that includes pack-years and cigarettes
per day, the parameter for cigarettes per day
represents the comparison of risk for exposure
delivered at lower intensity for longer duration
with risk for an equal total exposure delivered
at higher intensity for shorter duration (Lubin
and Caporaso 2006). We use this framework
to analyze inhalation of airborne inorganic
arsenic in a cohort mortality study of smelter
workers conducted in Montana (Lee and
Fraumeni 1969; Lee-Feldstein 1983; Lubin
et al. 1981, 2000).
Our goal of modeling the cumulative air-
borne arsenic exposure and arsenic concentra-
tion is to estimate a descriptive function that
deﬁnes the modifying effect of concentration
on the association between cumulative expo-
sure and respiratory cancer. This effect modi-
fication is conceptually similar to the “dose
rate effective factor” used in radiation epi-
demiology that describes for a speciﬁc type of
radiation the effects on disease risk of total
radiation dose delivered at lower (protracted
or highly fractionated) dose rates compared
with the effects at higher (or acute) dose rates
(National Research Council 2006).
Materials and Methods
Data. The cohort study enrolled workers
employed at a Montana copper smelter for ≥ 1
year before 1957, with follow-up starting 1 year
after initial employment or 1 January 1938,
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BACKGROUND: Inhalation of high levels of airborne inorganic arsenic is a recognized cause of
respiratory cancer. Although multiple epidemiologic studies have demonstrated this association,
there have been few analyses of the mathematical relationship between cumulative arsenic expo-
sure and risk of respiratory cancer, and no assessment as to whether and how arsenic concentra-
tion may modify this association.
OBJECTIVES: The objective is an evaluation of the shape of the relationship between respiratory
cancer mortality and cumulative inhaled arsenic exposure among copper smelter workers, and the
modiﬁcation of that relationship by arsenic concentration.
METHODS: We used Poisson regression methods to analyze data from a cohort of arsenic-exposed
copper smelter workers under a linear-exponential model for the excess relative risk.
RESULTS: Within categories of arsenic concentration, the association between respiratory cancer
and cumulative arsenic exposure was consistent with linearity. The slope of the linear relationship
with cumulative exposure increased with increasing arsenic concentration category. 
CONCLUSIONS: Our results suggested a direct concentration effect from inhaled inorganic arsenic,
whereby the excess relative risk for a fixed cumulative exposure was greater when delivered at a
higher concentration and shorter duration than when delivered at a lower concentration and
longer duration.
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[Online 23 July 2008]whichever was later (Lee and Fraumeni 1969).
The present analysis included 8,014 workers
followed through 1989 (Lubin et al. 2000). We
determined vital status from the National
Death Index (http://www.cdc.gov/nchs/
ndi.htm) and other sources, with causes of
death recorded from death certiﬁcates. A total
of 4,930 (62%) workers were deceased.
Following previous analyses of this cohort, we
consider respiratory cancer mortality as the
primary outcome.
In the 1960s, investigators ranked each
work site from 1 to 10 for its potential arsenic
exposure and classified each site as “heavy”
(ranks 8–10), “medium” (ranks 4–7), or
“light” (ranks 1–3) arsenic exposure areas (Lee
and Fraumeni 1969). We classified unspeci-
ﬁed or unknown work areas as light exposure
areas. We subsequently updated employment
information through September 1977 (Lee-
Feldstein 1986). Using 702 measurements of
airborne arsenic from 1943 through 1958 and
estimates of workers’ exposure times, investi-
gators computed time-weighted average
arsenic concentrations for light, medium, and
heavy arsenic-exposed areas as 0.29, 0.58, and
11.3 mg/m3, respectively (Morris 1978). For
each year of follow-up, we computed a cumu-
lative exposure index in mg/m3-year, denoted
d, as the product of years worked in light (L),
medium (M), and heavy (H) exposure areas
and the corresponding concentration—that is,
d = 0.29 × L + 0.58 × M + 1.13 × H—where
we down-weighted heavy exposure areas by a
factor of 0.1 to reflect use of air filtration
masks. This a priori choice of weight was
similar to an empirically derived, risk-based
estimate of weight (Lubin et al. 1981).
Many workers had recorded ages at last
employment of < 40 and 50 years. Because
there was no information on exposures after the
workers left the smelter, we repeated analyses
using person-years and respiratory cancer deaths
in current workers, recent former (< 5 years)
workers, and workers with last employment at
≥ 50 years of age to minimize effects of unmea-
sured exposures. The restricted subset included
261 respiratory cancer cases and 144,851 per-
son-years. The number of respiratory cancer
cases differed from a previous report (n = 252)
(Lubin et al. 2000) because of a modified
deﬁnition of the restrictions.
Statistical analysis. We assumed survival
time follows a piecewise exponential distribu-
tion and applied Poisson regression methods.
We summarized deaths from respiratory cancer
and person-years of follow-up in a multiway
contingency table deﬁned by attained age (nine
levels: < 45, 45–49, . . . ,75–79, ≥ 80), calendar
year (10 levels: 1935–39, . . . ,1985–90), cumu-
lative arsenic exposure (mg/m3-year; 18 levels:
< 0.25, 0.25–0.49, 0.50–0.74, 0.75–0.99,
1.0–1.4, 1.5–1.9, 2.0–3.9, . . . , 22–24.9,
≥ 25), mean arsenic concentration (mg/m3;
eight levels: 0, 0.01–0.29, 0.3–0.39, 0.4–0.49,
0.5–0.59, 0.6–0.79, 0.8–0.99, ≥ 1.0), years
since last arsenic exposure (three levels: < 5,
5–14, ≥ 15), and place of birth (two levels: U.S.
or foreign born). For each cell of the cross-clas-
siﬁcation, we computed person-year–weighted
means for the cross-classification variables.
Because all workers were exposed to arsenic, we
used age-speciﬁc and calendar-year-speciﬁc U.S.
mortality rates for respiratory cancer in white
males as a nonexposed referent population
(Breslow and Day 1987).
We deﬁned indicator variables ci, i = 1, . .
. , I, for I concentration categories where ci =
1 for intensities within category i and zero
otherwise, and modeled disease rate r(x,d,c) as
r(x,d,c) = exp(αT x) RR(d,c) 
= exp(αT x)(1 + Σγ i ci d), [1]
where d is cumulative arsenic exposure and c
is arsenic concentration. The vectors of vari-
ables x and parameters α, where T denotes
vector transpose, describe disease rates in non-
exposed workers. Within concentration cate-
gory i, RRs are linear in d; that is, RR(d,c) = 1
+ γi d, where γi is the slope of the linear expo-
sure–response, or ERR/mg/m3-year (ERR,
excess relative risk). We used Wald-type con-
ﬁdence intervals (CIs) for γi after reparameter-
izing γi as exp(γi*) to avoid range restrictions.
Factoring out γ1, we rewrote RR(d,c) as
RR(d,c) = 1 + γ1 d Σ (γi/γ1) ci,
which suggested the following model for con-
tinuous concentration:
RR(d,c) = 1 + β d g(c), [2]
where β deﬁned ERR/mg/m3-year at g(c) = 1.
The g(.) function represents the modifying
effects of arsenic concentration on the expo-
sure–response relationship. Preliminary analy-
sis suggested using the power form g(c) =
exp{φ ln(c)}, where φ > 0, φ = 0, or φ < 0
denotes a direct (increasing), constant (no
variation), or inverse (decreasing) concentra-
tion effect, respectively. Model fit did not
improve with the addition of c or ln(c)2.
We extended model 1 to
RR(d,c) = 1 + Σγ i ci d exp(δi d)[ 3 ]
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Table 1. Descriptive statistics for the Montana cohort study of copper smelter workers.
Characteristic All data Restricted dataa
No. of workers 8,014 7,887b
Person-years 256,850 144,851
Follow-up years 1938–1989 —
Mean cumulative arsenic exposurec (mg/m3-years) 3.7 5.4
Mean airborne arsenic concentrationc (mg/m3) 0.35 0.36
Mean durationc (years) 10.3 14.9
Respiratory cancer cases
No. 446 261
Mean cumulative arsenic exposure (mg/m3-years) 7.0 10.4
Mean airborne arsenic concentration (mg/m3) 0.41 0.40
Mean duration (years) 17.4 26.0
Crude respiratory cancer mortality rate × 1,000 1.74 1.80
aPerson-years in current and recent former (< 5 years) workers and workers with last employment at ≥ 55 years of age.
bNumber of workers contributing person time. cPerson-years weighted mean.
Table 2. Summary data, respiratory cancer mortality rates, unadjusted and adjusted SMRs relative to U.S. white males by cumulative arsenic exposure (mg/m3-years)
and arsenic concentration (mg/m3) for the Montana cohort study of copper smelter workers.
Cumulative arsenic exposure (mg/m3-years) Mean arsenic concentration (mg/m3)
< 0.75 0.75–1.99 2.0–4.9 5.0–9.9 10.0–14.9 ≥ 15.0 0.29 0.30–0.39 0.40–0.49 ≥ 0.50
Cases 62 96 74 83 84 47 239 74 29 104
Person-years 71424.0 66757.4 55332.2 39257.0 16804.7 7274.7 167583.2 39757.0 14853.6 34656.4
Mean 0.47 1.24 3.43 7.27 11.9 21.9 0.29 0.34 0.45 0.65
Crude rate × 1,000 0.87 1.44 1.34 2.11 5.00 6.46 1.43 1.86 1.95 3.00
SMR 0.97 1.50 1.35 1.49 2.40 3.62 1.30 1.61 1.81 2.59
95% CI 0.8–1.3 1.2–1.8 1.1–1.7 1.2–1.8 1.9–3.0 2.7–4.8 1.1–1.5 1.3–2.0 1.3–2.6 2.1–3.1
SMRa 0.84 1.28 1.08 1.11 1.68 2.35 1.02 1.32 1.47 2.00
90% CI 0.6–1.1 1.0–1.6 0.9–1.4 0.9–1.4 1.4–2.1 1.8–3.1 0.9–1.2 1.1–1.7 1.0–2.1 1.7–2.4
aSMRs adjusted for differences by calendar period and country of birth between rates of respiratory cancer in U.S. males and estimated respiratory cancer rates in a hypothetical group
of nonexposed workers.to evaluate departure from linearity, where δi
reﬂects concavity (δi < 0) or convexity (δi > 0)
of the ERRs with cumulative exposure for the
ith concentration category. The null hypothe-
sis δi = 0 speciﬁed no departure from linearity.
We applied a similar extension to model 2.
Because all workers were exposed, we
included the natural logarithm of the age- and
year-specific respiratory cancer rates of U.S.
males as a ﬁxed offset variable (x) to represent
rates in nonexposed workers. The model thus
represented a regression equation for stan-
dardized mortality ratios (SMR) (Breslow and
Day 1987). Although model 2 reflected
relative SMRs, we refer to quantities as RRs.
For analyses, we used the Epicure suite of
programs (Preston et al. 2004).
Results
The person-year–weighted mean cumulative
arsenic exposure was 3.7 mg/m3-years, with a
crude respiratory cancer mortality rate of 1.73
per 1,000 person-years, based on 446 total
respiratory cancer deaths (Table 1). The SMR
for respiratory cancer was 1.56 (95% CI,
1.4–1.7). In the restricted data, the mean
cumulative arsenic exposure was 5.4 mg/m3-
years, the crude respiratory mortality rate per
1,000 person-years was 1.80, and the SMR
was 1.87 (95% CI, 1.7–2.1). 
SMRs increased with cumulative arsenic
exposure and with arsenic concentration
(Table 2). The SMR in the lowest concentra-
tion category was significantly elevated, sug-
gesting a difference between respiratory cancer
mortality rates for U.S. males and a hypotheti-
cal group of nonexposed workers. We fitted
model 1 with continuous cumulative arsenic
exposure and six categories of arsenic concen-
tration and estimated respiratory cancer rates
in a hypothetical group of nonexposed workers
relative to the standard population. After
adjustment for arsenic exposure, SMRs for
nonexposed workers were 3.10 (95% CI,
2.3–4.2), 2.22 (95% CI, 1.6–3.1), and 1.44
(95% CI, 1.1–2.0) for calendar periods
< 1960, 1960–69, and ≥ 1970, respectively,
and the effect of U.S. birth relative to foreign
birth was 0.67 (95% CI, 0.5–0.9). SMRs did
not vary significantly with attained age. We
included offset parameters fixed at the loga-
rithms of these “nonexposed” SMRs to adjust
for differences between “nonexposed” workers
and the standard population. After adjustment,
SMRs increased with cumulative arsenic expo-
sure and with arsenic concentration, but at a
lesser rate of increase (Table 2).
Within each arsenic concentration category,
RRs increased with cumulative arsenic exposure
(Figure 1). Two characteristics in the ﬁgure are
noteworthy. First, RRs by cumulative arsenic
exposure were consistent with linearity within
each concentration category. Tests of the null
hypothesis of no departure from linearity were
not rejected. Second, estimates of the slope
parameters γi (i.e., the ERR/mg/m3-year) varied
signiﬁcantly (p-value for homogeneity of slopes,
p = 0.02) and generally increased, suggesting a
greater exposure–response relationship with
increasing arsenic concentration.
The change in the ERR/mg/m3-year esti-
mate (i.e., the slope) represents the effect
modiﬁcation by arsenic concentration of the
relationship between respiratory cancer and
cumulative arsenic exposure. Figure 2 plots
the slope estimate by mean arsenic concentra-
tion for six concentration categories (square
symbols, with CIs omitted for clarity), the ﬁt-
ted model 2 using continuous data (solid line),
its pointwise 95% CI (dashed lines), and the
model for no variation with concentration
(model 2 with φ = 0; dotted line). The ERR/
mg/m3-year estimate (β) was β = 0.115 (95%
CI 0.07–0.19) (Table 3), and varied signifi-
cantly with arsenic concentration (p < 0.01).
After adjusting for cumulative arsenic expo-
sure, the ERR/mg/m3-year increased with
increasing concentration (estimate of φ was
1.123 (95% CI, 0.41–1.84). Results in the
restricted data were similar.
Using model 2, we evaluated time since last
arsenic exposure as a modifier of the arsenic
exposure–response relationship. We focus on
the restricted data, although we show results for
all data for completeness. Although variations
were not statistically signiﬁcant, the cumulative
arsenic exposure effect (β) decreased with time
since last arsenic exposure by factors of 1.0, 0.8,
and 0.2 for < 5, 5–14, and ≥ 15 years since last
exposure, respectively (Table 3; change in
deviance = 2.6 and p = 0.27 comparing models
B0-R and T1-R; or change in deviance = 1.2
and p = 0.55 comparing models T2-R and
T3-R). The arsenic concentration effect (φ) also
varied with time since last exposure, but
changes in deviance were smaller (Table 3;
change in deviance = 1.9 and p = 0.39 compar-
ing models B0-R and T2-R, or change in
deviance = 0.5 and p = 0.78 comparing T1-R
and T3-R).
In the restricted data, there was a sugges-
tion of declining arsenic effects with attained
age, but no preference for effect modiﬁcation
of age with either cumulative arsenic exposure
or arsenic concentration.
Discussion
In our study of copper smelter workers, RRs
for respiratory cancer increased linearly with
cumulative arsenic exposure within categories
of arsenic concentration. In addition, we found
a direct concentration effect, whereby the slope
of the linear exposure–response relationship
increased with arsenic concentration. This pat-
tern implied that for equal cumulative arsenic
exposure, the RR of respiratory cancer mortal-
ity was greater for cumulative arsenic exposure
delivered at higher concentration for shorter
duration compared with cumulative exposure
delivered at lower concentration for longer
Inhaled arsenic and respiratory cancer mortality
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Figure 1. RRs of respiratory cancer mortality by categories of cumulative arsenic exposure (mg/m3-years)
and arsenic concentration (mg/m3) relative to U.S. mortality rates for white males, adjusted to nonexposed
workers, and fitted linear ERR models for cumulative arsenic exposure: 0.29 mg/m3 (A), 0.30–0.39 mg/m3
(B), 0.40–0.49 mg/m3 (C), and ≥ 0.50 mg/m3 (D). Estimates of the ERR per mg/m3-year and 95% CIs for the
four concentration categories were as follows: A, 0.016 (–0.005 to 0.041); B, 0.067 (0.024 to 0.119); C, 0.077
(0.017 to 0.159); D, 0.072 (0.043 to 0.107).
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As: ≥ 0.50 mg/m3 As: 0.40–0.49 mg/m3duration. The increase in the exposure–
response relationship within each arsenic con-
centration category occurred for the full range
of concentrations experienced by smelter work-
ers, suggesting that the direct concentration
effect was not rate limited within this range.
One explanation for the impact of arsenic
concentration on the association between
cumulative arsenic exposure and respiratory
cancer may be found in the concentration-
dependent ability of cells to methylate and
detoxify arsenic. Although human popula-
tions differ, most humans exposed to arsenic
excrete 10–30% inorganic arsenic, 10–20%
monomethylarsonic acid [MMA(V) and
MMA(III)], and 60–80% dimethylarsinic
acid [DMA(V) and DMA(III)]. The penta-
valent metabolites MMA(V) and DMA(V)
are generally considered less toxic than inor-
ganic arsenite or arsenate. Trivalent methy-
lated arsenic metabolites are more genotoxic
than inorganic arsenite both in vitro and
in vivo (Styblo et al. 2002). Although
MMA(III) and DMA(III) can be measured in
urine, epidemiologic studies to date have not
measured trivalent arsenicals because of the
preservation techniques required (Aposhian
et al. 2000; Le et al. 2000; Mandal et al. 2001;
Valenzuela et al. 2005). Epidemiologic studies
have used the percent MMA of total inorganic
arsenic and the MMA:DMA ratio as surrogate
markers of methylation efﬁciency of ingested
arsenic, with increased levels of excreted per-
cent MMA and MMA:DMA ratio in urine
indicating reduced methylation efficiency.
Studies of arsenic in drinking water conducted
in Taiwan, Argentina, Bangladesh, and certain
areas of the United States have reported ele-
vated risks of bladder and skin cancers associ-
ated with an increased percent MMA in urine,
as well as a greater MMA:DMA ratio (Ahsan
et al. 2007; Chen et al. 2003a, 2003b; Hsueh
et al. 1997; Pu et al. 2007; Steinmaus et al.
2006; Yu et al. 2000). These ﬁndings are sup-
ported by toxicologic studies showing that
methylated arsenicals, particularly MMA(III),
have a greater afﬁnity than the nonmethylated
forms for protein binding to monothiol,
dithiol, and trithiol sites, which can disrupt a
number of processes, including gene transcrip-
tion, glutathione synthesis, DNA methylation,
DNA repair, cell division, generation of reactive
oxygen species, and signal transduction path-
ways within cells (Cullen and Reimer 1989;
Kitchin and Wallace 2008; Kumagai and Sumi
2007; Lin et al. 1999, 2001; Mass et al. 2001;
Petrick et al. 2001; Styblo et al. 2000; Styblo
and Thomas 1997). In addition, studies of uri-
nary arsenic methylation patterns of healthy
individuals exposed to arsenic in drinking water
have shown increased percent MMA relative to
total urinary arsenic (Hopenhayn-Rich et al.
1996b), whereas the percentage of inorganic
arsenic and the MMA:DMA ratio decreased
when the arsenic concentration in drinking
water was reduced to lower levels (Hopenhayn-
Rich et al. 1996a). These ﬁndings suggest that
the mechanisms through which arsenic is
methylated and excreted can become rate-
limited at higher concentrations, perhaps
through several steps including enzyme-
catalyzed methylation of arsenic through
S-adenosyl methionine, or glutathione synthesis
(Waters et al. 2004).
The toxicologic effects of arsenic described
above are multifaceted. However, toxicologic
studies conducted to date support only the
notion that concentration of exposure has a
direct impact on the degree of toxicity and/or
DNA damage acquired. Total cumulative
arsenic exposure is a function of both concen-
tration and duration of arsenic exposure. Our
ﬁndings suggest that rates of arsenic biotrans-
formation and excretion are concentration
dependent. Toxicologic studies designed to
compare cellular and genetic toxicity at a given
total cumulative dose delivered at different dose
rates are needed to enhance understanding of
the mechanistic implications of our results.
Consistent with our ﬁndings, two epidemi-
ologic studies have suggested that the toxic
effects from cumulative arsenic exposure in
drinking water are greater among individuals
exposed at higher, as opposed to lower, con-
centrations. In a case–control study of arsenic-
related skin lesions in a screened population in
Bangladesh, about 70% of subjects consumed
drinking water with arsenic concentrations
> 50 µg/L (Rahman et al. 2006). For similar
levels of cumulative arsenic exposure, the odds
ratios were higher for subjects with older ages
at ﬁrst exposure compared with those younger
at first exposure. Because older age at first
exposure would reflect shorter duration of
exposure, the results suggested higher risks for
cumulative exposures with shorter durations
and correspondingly higher concentrations, as
we observed for lung cancer among smelter
workers. In a case–control study of bladder
cancer in New Hampshire, odds ratios among
smokers increased with higher concentrations
of toenail arsenic, with risks being greater
among individuals with shorter (< 15 years)
compared with longer residence in the current
home (Karagas et al. 2004).
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Table 3. Results of modeling the RRa of respiratory cancer by cumulative arsenic exposure and arsenic
concentration and variations by time since last exposure (TSLE) and attained age: Montana cohort study
of copper smelter workers.
TSLE (θ TSLE):
Model β < 5, 5–14, ≥ 15 φφ TSLE Devianceb
B0c 0.115 1.123 —
T1 0.120 1.00, 0.83, 1.20 1.153 0.5
T2 0.115 0.923, 1.278, 2.077 1.3
T3 0.095 1.00, 1.02, 2.52 0.723, 1.095, 2.661 3.7
B0-Rc 0.083 0.822 —
T1-R 0.102 1.00, 0.75, 0.18 0.848 2.6
T2-R 0.085 0.632, 1.111, 3.486 1.9
T3-R 0.095 1.00, 0.99, 0.11 0.739, 1.240, 17.53 3.1
Age (θ Age):
Model β < 60, 60–69, ≥ 70 φφ Age Devianceb
B0c 0.115 1.123 —
A1 0.153 1.00, 0.88, 0.52 1.175 2.2
A2 0.115 1.285, 1.012, 1.187 0.2
A3 0.200 1.00, 0.67, 0.20 1.830, 1.153, 0.077 4.9
B0-Rc 0.083 0.822 —
A1-R 0.088 1.00, 0.88, 0.66 0.878 0.7
A2-R 0.082 1.118, 0.813, 0.678 0.3
A3-R 0.156 1.00, 0.64, 0.20 1.724, 1.001, –0.281 4.0
aRR model: RR = 1 + β d θf exp{φf ln(c)}, where d is cumulative arsenic exposure in mg/m3-years, and c is airborne arsenic
concentration in mg/m3. Subscript f denotes categories of TSLE or attained age and represents multiple parameters
either multiplying the ERR per mg/m3-year (β) or distinct categories for the effects of arsenic concentration. bChange in
deviance from the base model, B0. Difference in deviances provides a likelihood ratio test of the added parameters.
cModels ﬁt to all cohort data or to restricted data, denoted by “R,” including person-time of workers with time since last
exposure < 5 years or age last exposure ≥ 50. Estimates and 95% CIs: B0 parameters (β and φ), 0.115 (0.07–0.19) and 1.123
(0.41– 1.84); B0-R parameters, 0.083 (0.04–0.15) and 0.822 (0.01–0.63).
Figure 2. Estimates of ERR per mg/m3-year based on
a linear RR model within six categories of arsenic
concentration (square symbols), ﬁtted model 2 (solid
line), its pointwise, two-sided, Wald 95% CI (dashed
lines), and model 2 omitting variation with concen-
tration (dotted line; ERR/mg/m3/year = 0.04756).
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0.2 0.4 0.6 0.8 1.0 1.2A threshold for the carcinogenic effects of
arsenic in drinking water at about 150 µg/L,
below which there is no risk from exposure,
has been suggested (Lamm et al. 2006).
Although studies of noncancer outcomes,
such as arsenical dermatoses, cardiovascular
disease, and cerebrovascular disease, do not
support a threshold (Ahsan et al. 2006; Engel
et al. 1994; Rahman et al. 2006; Yu et al.
2006), studies of cancer outcomes after rela-
tively low levels of exposure have been limited
by low power and potential exposure mis-
classiﬁcation (Cantor and Lubin 2007).
Our results may inform the exposure
threshold issue. In areas of Taiwan with
endemic blackfoot disease, Bates et al. (1992)
estimated that consuming drinking water with
470 µg/L arsenic resulted in a lifetime intake of
30,000 mg arsenic. Ingestion of drinking water
with 150 µg/L arsenic therefore corresponds
approximately to a lifetime intake of 9,600 mg
arsenic. Measurement of urinary arsenic and its
metabolites serves as a measure of absorption of
inhaled arsenic through the respiratory tract,
because arsenic excretion occurs mainly through
the kidneys (World Health Organization 2001).
In a study of smelter workers in Tacoma,
Washington, investigators empirically derived
the following relationship between inhaled and
urinary arsenic levels: airborne arsenic in micro-
grams per cubic meter = 0.0064 (urine arsenic
in micrograms per liter)1.924 (Enterline et al.
1987). In our data, mean airborne arsenic con-
centrations for the four categories in Figure 1
ranged from 0.29 to 0.65 mg/m3, and therefore
correspond roughly to urinary arsenic levels
from 263 to 400 µg/L. Assuming 2 L urine per
day, 250 working days per year, no other
sources of arsenic and no accumulation of
arsenic in the body (Bates et al. 1992), the
mean durations of exposure, which ranged
from 9.7 to 12.1 years for the four categories,
correspond to mean total arsenic intakes of
1,315 (= 263 × 2 × 250 × 10 year/1,000),
1,420, 1,649, and 1,996 mg arsenic, respec-
tively. Thus, cumulative arsenic exposure in the
smelter workers corresponded to < 20% of the
lifetime arsenic intake at the postulated thresh-
old. Our ﬁnding of a linear relationship for the
RR of respiratory cancer mortality across the
full range of cumulative arsenic exposures
within each category of arsenic concentration
argues against a threshold at 150 µg/L.
In summary, our cohort study of copper
smelter workers revealed a linear relationship
between cumulative arsenic exposure and respi-
ratory cancer mortality within categories of
arsenic concentration. In addition, we found a
direct concentration effect on the exposure–
response relationship, indicating that for a ﬁxed
level of cumulative arsenic exposure, inhalation
of higher concentrations of arsenic over shorter
durations was more deleterious than inhalation
of lower concentrations over longer durations.
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